Switch theme
Sign up to access all valuation multiples
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
2004
624
LTM Revenue $446M
LTM EBITDA $182M
$4.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
ADMA Biologics has a last 12-month revenue of $446M and a last 12-month EBITDA of $182M.
In the most recent fiscal year, ADMA Biologics achieved revenue of $426M and an EBITDA of $148M.
ADMA Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See ADMA Biologics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $258M | $426M | XXX | XXX | XXX |
| Gross Profit | $35.3M | $88.9M | XXX | XXX | XXX |
| Gross Margin | 14% | 21% | XXX | XXX | XXX |
| EBITDA | $5.1M | $148M | XXX | XXX | XXX |
| EBITDA Margin | 2% | 35% | XXX | XXX | XXX |
| Net Profit | -$65.9M | -$28.2M | XXX | XXX | XXX |
| Net Margin | -26% | -7% | XXX | XXX | XXX |
| Net Debt | $56.3M | $79.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, ADMA Biologics's stock price is $21.
ADMA Biologics has current market cap of $5.0B, and EV of $4.9B.
See ADMA Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.9B | $5.0B | XXX | XXX | XXX | XXX | $0.55 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, ADMA Biologics has market cap of $5.0B and EV of $4.9B.
ADMA Biologics's trades at 11.1x LTM EV/Revenue multiple, and 27.1x LTM EBITDA.
Analysts estimate ADMA Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for ADMA Biologics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.9B | XXX | XXX | XXX |
| EV/Revenue | 11.6x | XXX | XXX | XXX |
| EV/EBITDA | 33.5x | XXX | XXX | XXX |
| P/E | 25.1x | XXX | XXX | XXX |
| P/E/Growth | 2.2x | XXX | XXX | XXX |
| EV/FCF | 44.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpADMA Biologics's NTM/LTM revenue growth is 20%
ADMA Biologics's revenue per employee for the last fiscal year averaged $0.7M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, ADMA Biologics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate ADMA Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for ADMA Biologics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 65% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 35% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 2785% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 54% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.7M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 19% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
ADMA Biologics acquired XXX companies to date.
Last acquisition by ADMA Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . ADMA Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was ADMA Biologics founded? | ADMA Biologics was founded in 2004. |
| Where is ADMA Biologics headquartered? | ADMA Biologics is headquartered in United States of America. |
| How many employees does ADMA Biologics have? | As of today, ADMA Biologics has 624 employees. |
| Who is the CEO of ADMA Biologics? | ADMA Biologics's CEO is Mr. Adam S. Grossman. |
| Is ADMA Biologics publicy listed? | Yes, ADMA Biologics is a public company listed on NAS. |
| What is the stock symbol of ADMA Biologics? | ADMA Biologics trades under ADMA ticker. |
| When did ADMA Biologics go public? | ADMA Biologics went public in 2013. |
| Who are competitors of ADMA Biologics? | Similar companies to ADMA Biologics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of ADMA Biologics? | ADMA Biologics's current market cap is $5.0B |
| What is the current revenue of ADMA Biologics? | ADMA Biologics's last 12-month revenue is $446M. |
| What is the current EBITDA of ADMA Biologics? | ADMA Biologics's last 12-month EBITDA is $182M. |
| What is the current EV/Revenue multiple of ADMA Biologics? | Current revenue multiple of ADMA Biologics is 11.1x. |
| What is the current EV/EBITDA multiple of ADMA Biologics? | Current EBITDA multiple of ADMA Biologics is 27.1x. |
| What is the current revenue growth of ADMA Biologics? | ADMA Biologics revenue growth between 2023 and 2024 was 65%. |
| Is ADMA Biologics profitable? | Yes, ADMA Biologics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
